Abstract
CY and L-PAM potentiated specific anti-tumor response in addition to their killing effect. The immunomodulating effect of a low dose of either CY or L-PAM was expressed in mice bearing large s.c. MOPC-315 plasmacytoma tumors.Cured mice were resistant to a challenge dose of the syngeneic tumor and their spleens contained specific cytotoxic T cells. Induction of specific anti-tumor response by a low dose of alkylating drugs was due to expression of “latent anti-tumor” capability. This fitted with the conception that “suppressed concomitant immunity” occurring in tumor-bearing animals can be activated. The immunomodulating activity of alkylating drugs was related to enhancement of T-cell functions impairment of suppressor T-celll activity,enhancement of effector T-cell activity and increase in production of cytokines at the tumor site. The target tumor killing activity of a low dose alkylating drug was dissociated from its immunomodulating activity by treating mice bearing a tumor resistant to an alkylating drug. A low dose of CY had an immunomodulating effect in human cancer such as reduction of ConA-induced suppressor cell activity in melanoma, some improvement in addition to use of melanoma vaccine, and potentiation of DTH in cancer patients. The immunomodulating effect of alkylating drugs suggest that their use might be beneficial not only for killing tumor cells but also for promoting specific anti-tumor immune response.
Keywords: Immunomodulating Anticancer Alkylating Drugs, CY and L-PAM, Immunogenicity, Cyclophosphamide, L-Phenyl alanine mustard, Concanavalin A, Bromovynil deoxyuridine, Polyethylene glycol 6000, Tumor infiltrated spleen cells, Adoptive chemoimmunotherapy, Macrophage inhibiting factor
Current Drug Targets
Title: Immunomodulating Anticancer Alkylating Drugs: Targets and Mechanisms of Activity
Volume: 2 Issue: 2
Author(s): S. Ben-Efraim
Affiliation:
Keywords: Immunomodulating Anticancer Alkylating Drugs, CY and L-PAM, Immunogenicity, Cyclophosphamide, L-Phenyl alanine mustard, Concanavalin A, Bromovynil deoxyuridine, Polyethylene glycol 6000, Tumor infiltrated spleen cells, Adoptive chemoimmunotherapy, Macrophage inhibiting factor
Abstract: CY and L-PAM potentiated specific anti-tumor response in addition to their killing effect. The immunomodulating effect of a low dose of either CY or L-PAM was expressed in mice bearing large s.c. MOPC-315 plasmacytoma tumors.Cured mice were resistant to a challenge dose of the syngeneic tumor and their spleens contained specific cytotoxic T cells. Induction of specific anti-tumor response by a low dose of alkylating drugs was due to expression of “latent anti-tumor” capability. This fitted with the conception that “suppressed concomitant immunity” occurring in tumor-bearing animals can be activated. The immunomodulating activity of alkylating drugs was related to enhancement of T-cell functions impairment of suppressor T-celll activity,enhancement of effector T-cell activity and increase in production of cytokines at the tumor site. The target tumor killing activity of a low dose alkylating drug was dissociated from its immunomodulating activity by treating mice bearing a tumor resistant to an alkylating drug. A low dose of CY had an immunomodulating effect in human cancer such as reduction of ConA-induced suppressor cell activity in melanoma, some improvement in addition to use of melanoma vaccine, and potentiation of DTH in cancer patients. The immunomodulating effect of alkylating drugs suggest that their use might be beneficial not only for killing tumor cells but also for promoting specific anti-tumor immune response.
Export Options
About this article
Cite this article as:
Ben-Efraim S., Immunomodulating Anticancer Alkylating Drugs: Targets and Mechanisms of Activity, Current Drug Targets 2001; 2 (2) . https://dx.doi.org/10.2174/1389450013348597
DOI https://dx.doi.org/10.2174/1389450013348597 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Signal Transduction Therapy: Challenges to Clinical Trial Design
Current Signal Transduction Therapy The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies New Avenue of Research: Antiepileptic Drug and Estradiol Neuroprotection in Epilepsy
Recent Patents on CNS Drug Discovery (Discontinued) Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews The Role of the Osteoimmune Axis in the Inflammation of the Inner Auditory Ear and with Regard to the Putative Anticarcinogenetic Principle: Part 2
Inflammation & Allergy - Drug Targets (Discontinued) Inhibitors of the HSP90 Molecular Chaperone: Attacking the Master Regulator in Cancer
Current Topics in Medicinal Chemistry Lipid Nanoparticles for the Delivery of Biopharmaceuticals
Current Pharmaceutical Biotechnology Increased Paternal Age and Child Health and Development
Current Pediatric Reviews Isolation and Phenotypic Characterisation of Stem Cells from Late Stage Osteoarthritic Mesenchymal Tissues
Current Stem Cell Research & Therapy Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Recent Advances in Developing Photosensitizers for Photodynamic Cancer Therapy
Combinatorial Chemistry & High Throughput Screening Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry More Good News About Polymeric Plant- and Algae-Derived Biomaterials in Drug Delivery Systems
Current Drug Targets Telomeres and Thyroid Cancer
Current Genomics